Nabi Biopharmaceuticals (NABI) Tops Q3 EPS by 2c
NABI Hot Sheet
Revenue Growth %: -93.4%Financial Fact:
Operating income (loss): -2.16M
Today's EPS Names:
TARO, BRLI, TLB, More
Nabi Biopharmaceuticals (NASDAQ: NABI) reports Q3 loss of $0.14, 2 cents better the analyst estimate of ($0.16).
You May Also Be Interested In
- UPDATE: Bristow Group (BRS) Reports Better-Than-Expected Q4 Results; Offers FY13 Outlook
- Infoblox (BLOX) Tops Q3 EPS by 4c; Guides Q4
- ATA, Inc. (ATAI) Misses Q4 EPS by 1c; Guides FY13 Revs Below
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
